XML 96 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue (Tables)
3 Months Ended
Sep. 30, 2019
Revenue From Contract With Customer [Abstract]  
Composition of Total Revenue by Product and U.S versus Rest of World

The following table presents detail regarding the composition of our total revenue by product and U.S versus rest of world, “RoW”:

 

 

 

Three months ended September 30,

 

 

 

2019

 

 

2018

 

(In millions)

 

U.S.

 

 

RoW

 

 

Total

 

 

U.S.

 

 

RoW

 

 

Total

 

Molecular diagnostic revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hereditary Cancer Testing

 

$

100.6

 

 

$

3.9

 

 

$

104.5

 

 

$

113.5

 

 

$

2.8

 

 

$

116.3

 

GeneSight

 

 

22.7

 

 

 

 

 

 

22.7

 

 

 

29.3

 

 

 

 

 

 

29.3

 

Prenatal

 

 

23.5

 

 

 

 

 

 

23.5

 

 

 

18.1

 

 

 

 

 

 

18.1

 

VectraDA

 

 

11.0

 

 

 

 

 

 

11.0

 

 

 

13.0

 

 

 

 

 

 

13.0

 

Prolaris

 

 

6.5

 

 

 

 

 

 

6.5

 

 

 

6.2

 

 

 

 

 

 

6.2

 

EndoPredict

 

 

0.5

 

 

 

1.8

 

 

 

2.3

 

 

 

0.3

 

 

 

2.1

 

 

 

2.4

 

Other

 

 

1.4

 

 

 

0.1

 

 

 

1.5

 

 

 

3.6

 

 

 

0.1

 

 

 

3.7

 

Total molecular diagnostic revenue

 

 

166.2

 

 

 

5.8

 

 

 

172.0

 

 

 

184.0

 

 

 

5.0

 

 

 

189.0

 

Pharmaceutical and clinical service revenue

 

 

8.5

 

 

 

5.9

 

 

 

14.3

 

 

 

7.6

 

 

 

5.7

 

 

 

13.3

 

Total revenue

 

$

174.7

 

 

$

11.7

 

 

$

186.3

 

 

$

191.6

 

 

$

10.7

 

 

$

202.3

 

Reconciliation of Deferred Revenue Balances A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

 

 

Three months ended

 

 

 

September 30,

 

 

 

2019

 

 

2018

 

Deferred revenue - beginning balance

 

$

2.2

 

 

$

2.6

 

Revenue recognized

 

 

(0.4

)

 

 

(1.7

)

Prepayments

 

 

0.3

 

 

 

1.6

 

Deferred revenue - Ending Balance

 

$

2.1

 

 

$

2.5